陈列类药物和住院治疗心力衰竭的老年患者的死亡率
JoAnne Micale Foody1, Rahman Shah, Deron Galusha
1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8025, USA. joanne.foody@yale.edu
Circulation
|February 24, 2006
概括
在住院治疗心力衰竭 (HF) 的老年患者中,使用他类药物与改善的存活率有关. 这表明他类药物可能是当前高频率治疗的宝贵补充,需要进一步调查.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 小规模研究表明,他类药物可以改善心力衰竭 (HF) 患者的死亡率.
- 这些发现对更广泛的高频人口的概括性仍然不清楚.
- 这项研究评估了老年HF患者全国样本中的他类药物的使用和存活率.
研究的目的:
- 评估他类药物使用与存活率之间的关联.
- 评估国家样本中的他类药物的作用,该样本是住院治疗高血压的老年患者.
主要方法:
- 对全国61,939名医疗保险受益者 (≥65岁) 的样本进行分析,这些受益者因高血压而住院.
- 分析局限于54,960名没有他类药物禁忌的患者.
- 使用了考克斯的比例危险模型,根据人口,临床,治疗和医院特征进行调整.
主要成果:
- 只有16.7%的符合条件的患者在出院时接受了他类药物;老年患者接受他类药物的可能性较低.
- 出院后的静止剂治疗与显著改善的1年和3年死亡率有关 (HR分别为0.80和0.82).
- 无论胆固醇水平或冠状动脉疾病状况如何,都观察到好处.
结论:
- 立方体治疗与老年HF患者的更好的长期死亡率有关.
- 表明他类药物作为HF的辅助治疗的潜在作用.
- 需要随机试验来确认他类药物在改善HF结局中的作用.
相关概念视频
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
